Publications by authors named "Natalia Perdek"
Article Synopsis
- - Vaccine development for SARS-CoV-2 in 2020 was essential for reducing COVID-19 severity, with the U.K. primarily using Pfizer's BNT162b2 and Oxford/AstraZeneca's ChAdOx1-nCoV-19 vaccines during the initial roll-out.
- - A study analyzed the effects of age, sex, BMI, and pre-vaccination antibody levels on immune responses in participants, revealing that younger age and existing antibodies led to stronger antibody responses.
- - Findings showed that the Pfizer vaccine produced higher antibody levels compared to the AstraZeneca vaccine, but age and BMI negatively impacted both cellular and humoral responses to vaccination.
Antibody responses to SARS-CoV-2 vaccines vary for reasons that remain poorly understood. A range of sociodemographic, behavioural, clinical, pharmacologic and nutritional factors could explain these differences. To investigate this hypothesis, we tested for presence of combined IgG, IgA and IgM (IgGAM) anti-Spike antibodies before and after 2 doses of ChAdOx1 nCoV-19 (ChAdOx1, AstraZeneca) or BNT162b2 (Pfizer-BioNTech) in UK adults participating in a population-based longitudinal study who received their first dose of vaccine between December 2020 and July 2021.
View Article and Find Full Text PDFObjective: To determine the effect of population level implementation of a test-and-treat approach to correction of suboptimal vitamin D status (25-hydroxyvitamin D (25(OH)D) <75 nmol/L) on risk of all cause acute respiratory tract infection and covid 19.
Design: Phase 3 open label randomised controlled trial.
Setting: United Kingdom.
In this population-based cohort of 7538 adults, combined immunoglobulin (Ig) G, IgA, and IgM (IgG/A/M) anti-spike titers measured after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination were predictive of protection against breakthrough SARS-CoV-2 infection. Discrimination was significantly improved by adjustment for factors influencing risk of SARS-CoV-2 exposure, including household overcrowding, public transport use, and visits to indoor public places. Anti-spike IgG/A/M titers showed positive correlation with neutralizing antibody titers (rs = 0.
View Article and Find Full Text PDFArticle Synopsis
- A prospective study in the UK analyzed factors influencing pre-vaccination antibody responses to SARS-CoV-2 among 11,130 vaccine-naive adults, tracking data collected via online questionnaires and blood tests.* -
- Of the participants, 15.2% tested positive for antibodies, with increased seropositivity linked to frontline healthcare jobs, international travel, high shopping frequency, higher BMI, South Asian ethnicity, and significant alcohol consumption.* -
- Among those who were seropositive, higher anti-Spike antibody levels were associated with similar risk factors and behaviors, emphasizing the role of BMI, ethnicity, occupation, travel, and shopping habits in antibody response.*